Does Bedaquiline kill all tuberculosis bacteria?

Bedaquiline is a new anti-tuberculosis drug with significant minimum inhibitory concentrations (MICs) for both drug-sensitive and drug-resistant tuberculosis. Bedaquiline is approved for the treatment of multidrug-resistant tuberculosis. Bedaquiline is effective in treating tuberculosis, but it cannot kill all tubercle bacilli.

Following the previous placebo-controlled Phase 2 trial(TMC 207-C208;NCT00449644), the current Phase 2, multicenter, open-label, single-arm trial(TMC 207-C209;NCT00910871)Studies were conducted to confirmbedaquiline’s safety and effectiveness. Patients with newly diagnosed or previously treated MDR-TB(Including pre-XDR-(pre-XDR)-TB or XDR-(XDR)-TB)receivedbedaquilinetreatment for 24weeks and continued background therapy with antituberculosis drugs in accordance with the National Tuberculosis Program treatment guidelines. Patients were evaluated during initiation of bedaquilinetreatment and for 120weeks after treatment. Of the 233 patients enrolled, 63.5% had MDR-TB and 18.9% Suffering from extensively drug-resistant tuberculosis, 16.3% suffered from extensively drug-resistant tuberculosis, of which 87.1% had taken second-line drugs before inclusion. Death16cases (6.9%). 20patients(8.6%)discontinued treatment before week 24most commonly due to adverse events or MDR-TB-related events. Adverse events are commonly associated with MDR-TB treatment. In the efficacy population(n=205), culture conversion at 120weeks (missing results classified as failed) was 72.2%, among patients with MDR-TB, former XDR-TB and XDR-TB, they were 73.1%, 70.5% and 62.2%, respectively. In this clinically relevant cohort of MDR-TB patients, the addition ofbedaquilineto the base regimen was well tolerated and resulted in favorable outcomes. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.

xa0